Explore how the study drug VK2735, a novel dual GLP-1/GIP receptor agonist, is being evaluated for effective weight management in adults with type 2 diabetes.
Those who qualify and choose to participate will be compensated up to $4,500 for 48 visits over approximately 88 weeks.
This clinical study is designed to see how well the study drug VK2735 helps improve weight management in adults with type 2 diabetes compared to a placebo. The study also looks at how well different doses of VK2735 are tolerated and how the body processes the drug.
If you qualify and choose to participate, there is a 73% chance you will receive the study drug and a 27% chance you will receive a placebo, however all participants will receive nutrition and lifestyle advice throughout the trial. A placebo is an inactive material that looks like VK2735 but does not contain any active study drug.
You will be on this study for approximately 88 weeks which will include a 4-week screening period, a 78-week treatment period, and a 6-week follow-up period. The study will require up to 48 in-clinic visits. If you qualify and choose to participate, you will be compensated up to $4,800 for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.
VK2735 is a dual GLP-1/GIP receptor agonist, developed by Viking Therapeutics, and has shown promising results in both human and animal studies for improving metabolic health. Previous research on VK2735 initiated in September 2023 successfully met its primary and secondary goals in February of 2024, showing significant weight loss in patients taking VK2735 compared to a placebo, with most side effects being mild or moderate. The study also indicated that VK2735 could support weight maintenance with less frequent dosing. For more information, visit the Viking Therapeutics website.
Those who qualify and choose to participate could receive:
Access to the investigational GLP-1/GIP weight management medication at no cost
Access to our top-tier team of board-certified physicians at no cost
Compensation up to $4,500 for 48 visits over 88 weeks
A research study or clinical trial is the process a potential new drug, device, procedure, or process goes through to prove that it is safe, tolerable and effective for the condition it is being studied for. Research studies are the only way to advance medicine for future generations.
Each study has its own set of inclusion and exclusion criteria that a participant must meet before they are allowed to participate in a study. Patients from all backgrounds and walks of life are encouraged to participate.
Every participant in every research study must go through the informed consent process. During this, the trial doctor and research team go over what will happen in the study, what treatments you might get, how long the trial is expected to last, what happens during visits, the potential risks and benefits, and many other important facts about the study. Participants may withdraw their consent and discontinue the study at any time for any reason.
A placebo looks like a treatment but does not have any active medicine in it. Researchers use placebos to help make sure any changes in the participants’ health are actually caused by the study treatment. You do not get to choose if you get the study treatment or the placebo, and you may not know if you get the placebo until after the study. Not all research studies use a placebo.
If studies do not include diverse participants, we cannot know if treatments work for everyone who needs them. Studies only tell researchers how something works for the participants of that study, and they may not work the same in people of different races, ethnicities, ages, or sexes.
All research studies must follow federal laws and ethical guidelines, including HIPAA. Studies must also be approved by an expert group called an institutional review board (IRB) that helps make sure the trial is fair and as safe as possible, and that any risks to the participants are worth the potential benefits.